{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityComment":"Weibull accelerated failure time model; adjusted for disease type and stem cell collection days; non-inferiority declared if 90% CI upper bound for acceleration factor \\< 1.133 (≤13.3% increase in discharge readiness time); one-sided α = 0.05; sample size for \\~80% power; O'Brien-Fleming futility boundary applied.","nonInferiorityType":"NON_INFERIORITY","pValue":"0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"26","value":"11"},{"groupId":"OG001","lowerLimit":"11","upperLimit":"29","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Will compare days to discharge readiness between the two groups.","dispersionType":"Full Range","groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG001","title":"Group II (auto HSCT)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 60 days","title":"Number of Days to Discharge","type":"PRIMARY","unitOfMeasure":"days"}